<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05081687</url>
  </required_header>
  <id_info>
    <org_study_id>4015-20</org_study_id>
    <nct_id>NCT05081687</nct_id>
  </id_info>
  <brief_title>Brazilian Total Neoadjuvant Therapy Trial</brief_title>
  <acronym>BRAZIL-TNT</acronym>
  <official_title>A Prospective Randomized Controlled Trial of Total Neo-adjuvant Therapy vs Conventional Chemo-radiation Aiming at Increasing Rates of Clinical Complete Response in Locally Advanced Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Israelita Albert Einstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Israelita Albert Einstein</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Standard therapy for localized rectal cancer includes chemotherapy and radiation therapy,&#xD;
      followed by a &quot;recovery&quot; period of 7-12 weeks, surgery and adjuvant chemotherapy for 3-6&#xD;
      months. Even though this protocol achieves high cure rates, many patients need a rectal&#xD;
      amputation with placement of definitive colostomies. About 10-20% of patients have a complete&#xD;
      clinical response to chemo-radiation and no tumor can be found in the surgical specimen.&#xD;
      These patients can be followed with close surveillance and avid surgery. The aim of this&#xD;
      study is to evaluate if a strategy including the use of a highly active chemotherapy called&#xD;
      &quot;FOLFIRINOX&quot; during the 12 weeks between the end of radiation therapy and evaluation for&#xD;
      surgery increases the rates of complete response and, therefore, allows more patients to&#xD;
      undergo non-surgical management.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult patients with locally advanced rectal cancer who have completed conventional&#xD;
      long-course chemo-radiation of 54Gy with capecitabine will be randomized 1:1 to a total&#xD;
      neo-adjuvant therapy (TNT) protocol or to a control group. Patients in the TNT arm will&#xD;
      receive 4 cycles of interval chemotherapy with FOLFIRINOX (5-FU, irinotecan, oxaliplatin)&#xD;
      between the end of chemo-radiation and re-staging and those in the control group will undergo&#xD;
      standard post-radiation care during this period. All patients will be re-staged with&#xD;
      colonoscopy and pelvic MRI 12 weeks after the end of chemo-radiation. Those with a complete&#xD;
      clinical response will be placed under a watch-and-wait protocol with digital rectal&#xD;
      examinations every 2 months and pelvic MRI and sigmoidoscopy every 6 months. Those wih&#xD;
      residual tumors will undergo resection with total mesorectal excision (TME). Patients with a&#xD;
      &quot;near complete response&quot;, as defined by a multidisciplinary tumor board, will be re-staged at&#xD;
      week 16 or 18 after chemo-radiation before undergoing surgery. Adjuvant chemotherapy will be&#xD;
      done following the local standard of care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized 1:1 to one of two arms: TNT and conventional therapy (control). Randomization will be stratified by study site and tumor stage (II vs III)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This is an open-label study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>cCR + PathCR</measure>
    <time_frame>12 weeks after the end of chemoradiation</time_frame>
    <description>Complete clinical response or pathological response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of R0 resection</measure>
    <time_frame>12 weeks</time_frame>
    <description>Rate of tumor resection with negative margins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of organ preservation</measure>
    <time_frame>6 months after surgery</time_frame>
    <description>Rate of patients who remain colostomy-free</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall toxicity</measure>
    <time_frame>12 weeks</time_frame>
    <description>Grade 3-4 toxicities according to CTCAE 4.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Total neoadjuvant therapy (TNT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 cycles of mFOLFIRINOX every 14 days:&#xD;
Oxaliplatin 85 mg/m2&#xD;
Irinotecan 150mg/m2&#xD;
5-FU 2.400mg/m2&#xD;
Dexamethasone 12mg&#xD;
Atropine 0.5mg&#xD;
Netupitant/palonosetron</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard post-radiation care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folfirinox</intervention_name>
    <description>5-FU 2400mg/m2; Oxaliplatin 85 mg/m2, Irinotecan 150mg/m2</description>
    <arm_group_label>Total neoadjuvant therapy (TNT)</arm_group_label>
    <other_name>mFOLFIRINOX</other_name>
    <other_name>FOLFOXIRI</other_name>
    <other_name>5-FU, oxaliplatin, irinotecan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;= 18 y/o&#xD;
&#xD;
          -  Biopsy-confirmed rectal adenocarcinoma&#xD;
&#xD;
          -  Tumor Stage T3+ or N+ M0&#xD;
&#xD;
          -  Adequate liver function (total bilirubin &lt; = 4.0)&#xD;
&#xD;
          -  Adequate kidney function (calculate creatinine-clearance &gt;=30ml/m2/min)&#xD;
&#xD;
          -  Adequate bone marrow function (Platelet counts &gt;=90.000, hemoglobin &gt;=8mg/dl,&#xD;
             neutrophile count &gt;= 1.500/cm3)&#xD;
&#xD;
          -  Completed chemo-radiation with at least 54Gy and capecitabine 1650mg/m2/d&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior tumor resection&#xD;
&#xD;
          -  Prior radiation to the pelvis&#xD;
&#xD;
          -  Prior chemotherapy for rectal cancer&#xD;
&#xD;
          -  Life expectancy &lt; 6 months&#xD;
&#xD;
          -  Unfit for surgery&#xD;
&#xD;
          -  Need for urgent/ immediate surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diogo Gomes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Israelita Albert Einstein</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diogo Gomes, MD</last_name>
    <phone>+55-11-2151-8056</phone>
    <email>diogo.gomes@einstein.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leticia Brito, MD</last_name>
    <phone>+55-11-2151-8056</phone>
    <email>leticia.brito@einstein.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Municipal Vila Santa Catarina</name>
      <address>
        <city>SÃ£o Paulo</city>
        <zip>04378-500</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diogo Gomes, MD</last_name>
      <phone>+55-11-2151-8056</phone>
      <email>diogo.gomes@einstein.br</email>
    </contact>
    <contact_backup>
      <last_name>Leticia Brito</last_name>
      <phone>+55-11-2151-8056</phone>
      <email>leticia.brito@einstein.br</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>https://hospitais.proadi-sus.org.br/</url>
    <description>Program of the Brazilian Ministry of Health that us sponsoring the trial</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 5, 2021</study_first_submitted>
  <study_first_submitted_qc>October 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rectal cancer</keyword>
  <keyword>Neoadjuvant chemo-radiation</keyword>
  <keyword>Total neoadjuvant therapy</keyword>
  <keyword>Watch-and-wait</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Folfirinox</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

